46 results about "Vascular malformation" patented technology

The present disclosure provides methods of treating cerebral cavernous malformations and Devic's disease with ROCK2 inhibitors. The present disclosure also provides pharmaceutical formulations for oral administration of ROCK2 inhibitors for the treatment of cerebral cavernous malformations and Devic's disease.

The present invention relates to a method of treating PIK3CA-Related Overgrowth Spectrum (PROS) more particularly, Congenital, Lipomatous, Overgrowth, Vascular Malformations, Epidermal Nevi and Spinal / Skeletal Anomalies and / or Scoliosis (CLOVES) syndrome. To date, there are no specific treatments for patients and no animal models of PROS to better understand the physiopathology of the disorder. Inventors developed a genetic mouse model of PROS that recapitulates the human disease and demonstrated the efficacy of BYL719. Based on these results they treated two patients, one adult and one child, with severe CLOVES syndrome using BYL719. The drug had a robust efficiency on disease in the two patients inducing quick recovery of all affected organs. Thus, the invention relates to a method of treating PROS in a subject in need thereof comprising the step of administrating the subject with a therapeutically effective amount of BYL719.

The present invention relates to a method of treating PIK3CA-Related Overgrowth Spectrum (PROS) more particularly, Congenital, Lipomatous, Overgrowth, Vascular Malformations, Epidermal Nevi and Spinal / Skeletal Anomalies and / or Scoliosis (CLOVES) syndrome. To date, there are no specific treatments for patients and no animal models of PROS to better understand the physiopathology of the disorder. Inventors developed a genetic mouse model of PROS that recapitulates the human disease and demonstrated the efficacy of BYL719. Based on these results they treated two patients, one adult and one child, with severe CLOVES syndrome using BYL719. The drug had a robust efficiency on disease in the two patients inducing quick recovery of all affected organs. Thus, the invention relates to a method of treating PROS in a subject in need thereof comprising the step of administrating the subject with a therapeutically effective amount of BYL719.

Apparatus is provided for treating a vascular malformation, including an orifice section, an occlusion section, and a connecting section. When the apparatus is unconstrained, the orifice and occlusion sections are shaped so as to define orifice-section and occlusion-section curves that wind around non-coaxial orifice-section and occlusion-section central axes, respectively, at changing distances from the axes. The orifice-section curve defines an orifice-section central opening. A projection of the occlusion-section curve occludes at least 25% of a orifice-section-central-opening cross-sectional area of an orifice-section central opening; the projection of the occlusion-section curve is in a direction along the orifice-section central axis, onto an orifice-section plane perpendicular to the orifice-section central axis. Other embodiments are also described.

The present application relates to a kind of hemangioma occlusion device, hemangioma occlusion treatment device and hemangioma occlusion system, hemangioma occlusion device includes mesh expansion structure and guide structure, the mesh expansion structure has from the unwinding state of spiral shape around from distal end to proximal end and the compressed state for being delivered from inside blood vessel to hemangioma;At least a part of the guide structure is arranged in the lumen of mesh expansion structure, and when the mesh expansion structure is in spiral shape, at least a part of the guide structure is unwound in the lumen of mesh expansion structure in spiral shape.The present application has the advantages of preventing hemangioma rupture, preventing vascular embolism, improving the coverage of tumor neck, promoting the formation of intratumoral thrombus, accelerating hemangioma embolism and the like while realizing stable and compliant tamponade.

The invention provides a developing agent which is modified iopamidol, a clinically safe nonionic hydrophilic developing agent iopamidol is subjected to structural modification, a hydrophilic side chain and a connecting arm are introduced, and the iopamidol is introduced into a gelatin degradable microsphere matrix with good biocompatibility in a covalent bonding manner; the degradable non-ionic X-ray developing microsphere with good biocompatibility is formed. Developing microspheres prepared by adopting the developing agent provided by the invention not only keep excellent X-ray developing performance, solve the problems of aggregation tendency and biocompatibility of traditional developing microspheres and realize real-time visual monitoring of an embolism process, but also have degradability and good biological safety, and are not only suitable for permanent embolism treatment, but also suitable for treatment of embolism. The solid developing embolism agent can also be expanded to the fields of temporary embolism, tissue engineering and the like, and the solid developing embolism agent with precise developing and safe degradation performance is provided for minimally invasive interventional therapy of diseases such as tumor intervention and vascular malformation.

The present invention relates to a pharmaceutical composition for preventing or treating cerebral cavernous malformation (CCM), comprising a transient receptor potential vanilloid 4 (TRPV4) inhibitor.

The invention belongs to the technical field of pathological science, and discloses application of TLSs in preparation of a product for prognosis evaluation of complex vascular malformation. The product realizes prognosis evaluation based on parameters of maturity, distribution and quantity of TLSs in a focus of complex vascular malformation; when the number of the TLSs in the parameter is larger and the maturity is higher, the associated information of the complex vascular malformation that the disease course is longer and the recurrence possibility is high is correspondingly output. The invention provides a specific evaluation standard of the TLSs in complex vascular malformation, and a prediction application value for prompting disease prognosis recurrence of the TLSs. The TLSs can be used as a pathological index for detecting recurrence prognosis by FAVA and PHOST, and the risk of postoperative recurrence of vascular malformation can be predicted by detecting the distribution, the number and the maturity of the TLSs. For pathologists with rich experiences, the maturity of TLSs can be evaluated according to HE slices, and the method has good sensitivity and specificity.

The invention relates to a medicine for preventing and treating cerebral cavernous malformation lesion and application thereof. The invention discloses a medicine which can inhibit the occurrence and growth of a cerebral cavernous malformation focus by inhibiting a molecular pathway of CCM, and also comprises analogues or derivatives of the medicine. The treatment of the CCM generally takes the brain as a drug target, the lower toxic and side effects particularly need to be concerned, and the drug disclosed by the invention has low side effects. The medicine provided by the invention can limit the occurrence of lesions in the initial stage of CCM, and is also suitable for preventing the progress of advanced lesions.

The utility model relates to the technical field of microwave ablation needles, and discloses a microwave ablation needle suitable for children vessel malformation, which comprises a microwave ablation needle body, a fixed seat is fixedly connected to the outer side of the right end of the microwave ablation needle body, a replacement mechanism is mounted on the microwave ablation needle body, the replacement mechanism is detachably connected with a female seat mechanism, and the female seat mechanism is detachably connected with the microwave ablation needle body. By means of the replacement mechanism and the female seat mechanism, if the same controller is needed, the microwave ablation needle body can be replaced according to needs, the microwave ablation needle body is disposable, the controller is a common part, and when different controllers are needed, the whole replacement mechanism with the microwave ablation needle body is replaced. At the moment, the whole replacement mechanism with the microwave ablation needle body is disposable, the microwave ablation needle body can be independently replaced in the replacement mechanism in the two modes, cost is reduced, children of different age groups and different physical conditions can use the microwave ablation needle more easily, and replacement operation is facilitated.

The present invention relates to a method of treating PIK3CA-Related Overgrowth Spectrum (PROS) more particularly, Congenital, Lipomatous, Overgrowth, Vascular Malformations, Epidermal Nevi and Spinal / Skeletal Anomalies and / or Scoliosis (CLOVES) syndrome. To date, there are no specific treatments for patients and no animal models of PROS to better understand the physiopathology of the disorder. Inventors developed a genetic mouse model of PROS that recapitulates the human disease and demonstrated the efficacy of BYL719. Based on these results they treated two patients, one adult and one child, with severe CLOVES syndrome using BYL719. The drug had a robust efficiency on disease in the two patients inducing quick recovery of all affected organs. Thus, the invention relates to a method of treating PROS in a subject in need thereof comprising the step of administrating the subject with a therapeutically effective amount of BYL719.

The invention relates to the technical field of biomedical materials, and provides zeolite polyvinyl alcohol organic-inorganic composite embolization microspheres as well as a preparation method and application thereof. The preparation method comprises the following steps: preparing nano zeolite with a blood coagulation function through ion exchange, dispersing the nano zeolite in silicone oil to form a continuous phase, and forming W / O type liquid drops from a polyvinyl alcohol dispersed phase solution and the continuous phase containing the nano zeolite by adopting a microfluidic technology; and crosslinking and curing by using an organic acid catalyst to obtain the zeolite polyvinyl alcohol organic-inorganic composite embolism microsphere with a physical embolism function and a procoagulant function. The zeolite polyvinyl alcohol organic-inorganic composite embolism microsphere takes cross-linked polyvinyl alcohol as a matrix, nano zeolite particles with specific functions are uniformly distributed on the surface, and the zeolite polyvinyl alcohol organic-inorganic composite embolism microsphere has a physical embolism function and a procoagulant function and has a wide application prospect in the fields of tumor embolism treatment, vascular malformation embolism, hemorrhagic disease treatment and the like; and a brand-new efficient embolism treatment solution is provided for clinic.

The present application provides use of a PI3Kα inhibitor in the manufacture of a medicament for treating a disease associated with a PIK3CA or / and TEK gene mutation. In particular, the present application provides use of a PI3Kα inhibitor CYH33 or a pharmaceutical composition comprising CYH33 in the manufacture of a medicament for preventing, treating or alleviating a PIK3CA-related overgrowth syndrome (PROS) and / or a PIK3CA-related vascular malformation (PRVM), and / or a TEK gene mutation-related vascular malformation.

Described herein is a patch delivery assembly for treating a target site and a method for deploying the same. The patch delivery assembly includes a patch installation frame having a self-expanding body extending between a proximal end and an open distal end and defining a lumen therethrough. The patch delivery assembly also includes a delivery cable having a distal end coupled to the proximal end of the patch installation frame and further defining the lumen, and a securement device extending through the lumen defined through the delivery cable and the patch installation frame, the securement device terminating in a distal working end including a securement mechanism. In a deployment configuration of the patch delivery assembly, the patch delivery assembly further includes a patch releasably coupled to the distal end of the patch installation frame, for securement to tissue of the target site using the securement mechanism.

The application provides application of bevacizumab in preparation of a medicine for inhibiting hemorrhagic lesions of cerebral vascular malformations, and belongs to the technical field of medicine application. The application firstly discovers and proves by experiments that bevacizumab can be used for binding free VEGF molecules in serum of a patient with a cavernous cerebral vascular malformation, thereby inhibiting a VEGF path, and having obvious inhibiting effect on symptomatic hemorrhagic lesions of the cavernous cerebral vascular malformation, and developing a new use of bevacizumab, and providing a new selection of drug treatment for the patient with the cavernous cerebral vascular malformation.

The application discloses a novel OCT space reconstruction method, which comprises the following steps: acquiring multiple coronary angiography image data at different angles; extracting coronary angiography images at the same moment in different cardiac cycles from the coronary angiography image data acquired at each angle; extracting a blood vessel skeleton according to the coronary angiography images; in the process of extracting the blood vessel skeleton, the coronary angiography images at different angles are included; multi-view stereo matching is performed by using deep learning, and matching correction is performed by using an epipolar geometry algorithm; a three-dimensional blood vessel skeleton is acquired according to the coronary angiography images after the matching correction; coronary OCT sequence images are acquired, and rearrangement is performed in combination with the direction of the three-dimensional blood vessel skeleton; body rendering is performed on the rearranged images, and a three-dimensional space model with a real posture is rendered. The method realizes prediction of invisible parts and guarantees the correctness of three-dimensional reconstruction of visible parts, and provides a data basis for screening of vascular deformity and the like in the later stage.

The present disclosure relates to a system for identifying the gene mutation type of a cerebral cavernous malformation (CCM) patient, and a system for determining a treatment plan for a cerebral cavernous malformation patient. The system provided by the present disclosure can determine the gene mutation type of a cerebral cavernous malformation patient based on a head computed tomography (CT) image and / or a magnetic resonance imaging (MRI) of the cerebral cavernous malformation patient, and therefore, the present disclosure provides a non-invasive method for determining the corresponding gene mutation type of a CCM patient, enriches the diagnosis method of CCM, and can provide a strong basis for the rationalization and targeted treatment of CCM.

The invention relates to a device (17) for treatment of body tissue, in particular for the permanent occlusion of varicose veins, preferably in the lower limbs, of varicocele and / or of vascular malformations and / or for the use in aesthetic surgeries, preferably laser assisted lipolysis, and / or for tumor treatment by means of laser induced thermotherapy and / or photodynamic therapy, and / or in particular for the irradiation of brain tissue, for ear-nose-throat applications, in particular necrosis of tissue, for surface disinfection by laser light, for dermatologic treatment, including application on skin and / or nails and / or for treatment of pilonidal sinus, anal fistula and / or hemorrhoids, by means of a light diffuser (13) for irradiating said tissue by laser light energy and / or by electromagnetic radiation, wherein the light diffuser (13) is designed to irradiate the radiation laterally with respect to a longitudinal center axis of the light diffuser (13) and endoluminally. According to the invention, a sliding layer (51) is provided on an outer surface, in particular the outermost surface, of a distal end of the diffuser (13) at least in certain regions, preferably in the region of the front distal end of the diffuser (13) and / or in the region of the energy emission of the diffuser (13), in particular completely, in particular to reduce friction with and / or in particular to reduce adhesion to said surrounding tissue.

The invention relates to a gene combination for detecting hemangioma and vascular malformation and application thereof. 62 genes Panel closely related to hemangioma and vascular deformity are excavated, and the Panel comprises a DNA detection gene and an RNA detection gene, and can be effectively applied to identification of hemangioma and vascular deformity driving gene mutation, genetic susceptibility genes and fusion genes which possibly exist, so that pathologists are guided to clear pathological diagnosis and typing; according to the gene detection panel for the hemangioma and the vascular malformation, the target treatment selection and genetic risk evaluation and screening of a patient are guided, the blank of lack of the gene detection panel special for the hemangioma and the vascular malformation at present is filled, the detection rate and sensitivity of the hemangioma and the vascular malformation are improved, and the problems of misdiagnosis and missed diagnosis caused by easy omission of the current detection panel are effectively solved.

The disclosure relates in part to the discovery that slow-flow vascular malformations (which can be venous and / or lymphatic) can be treated using direct intralesional delivery of an active drug, such as but not limited to a mTOR inhibitor, such as but not limited to temsirolimus, or a salt or solvate thereof.

Port wine birthmark, also known as port wine stain (PWS) is a skin discoloration characterized by red / purple patches caused by vascular malformation. In this disclosure, we propose a photoacoustic (PA) guided US focusing methodology for PWS treatment which combines the optical contrast-based selectivity with US penetration to focus the US energy onto the vasculature. The PA signals collected by the transducers when time-reversed and transmitted converge onto the PWS, thus, minimally affecting the neighboring tissue. We performed simulations that mimic realistic transducers and medium properties for this proof of concept study demonstrating the feasibility of the proposed methodology.

The invention relates to a puncture needle for injection virus in molding of cavernous blood vessel deformity of newborn mouse brain. The puncture needle comprises an operation handle, a limiting lug, a needle tube, a needle tube connector, a fiber grating recognition structure and a depth limiting structure. By arranging a fiber bragg grating recognition structure, in the penetrating process of a puncture needle, according to the FBG wavelength offset, a microprocessor receives an electric signal of a fiber FBG sensor, the microprocessor transmits the electric signal to a fiber bragg grating demodulator, the fiber bragg grating demodulator receives FBG reflection spectrum information, and a neural network model for deformation reconstruction of the puncture needle is constructed; micro deformation of the puncture needle is monitored, so that an experimenter is assisted in judging tissue resistance mutation in the puncture process, and accidental injury of blood vessels is prevented; by arranging the depth limiting structure and rotating the fine adjustment screw clockwise, the fine adjustment screw is in threaded fit with the inner side of the fixed seat, so that the connecting seat and the jacking mechanism are pushed to move towards the front end, the position of the jacking mechanism is changed, and the depth of the needle tube is changed.

An apparatus is provided for treating a vascular malformation. The apparatus includes an orifice section, an intra-vascular-malformation docking section, and a connecting section. The apparatus is configured such that, when unconstrained the orifice section is shaped so as to define an orifice-section curve that winds at least 2.5 turns around an orifice-section central axis at a changing distance from the orifice-section central axis, the intra-vascular-malformation docking section is shaped so as to define a docking-section curve that winds between 0.5 and 2 turns around a docking-section central axis at a changing or constant distance from the docking-section central axis, and a slope of the connecting-section is greater than a slope of the orifice-section. Other embodiments are also described.

Provided are methods of treating a cerebral cavernous malformation (CCM) and methods of treating cerebral aneurysm in a mammal with certain rho kinase inhibitors.

Described herein are methods of selectively targeting a cell expressing upregulated PI3K activity in a subject, the method comprising: administering to the subject a plurality of nanoparticles having an average diameter between 60 nm to 200 nm, the nanoparticles comprising: a polymer; and, one or more a pharmaceutical agents. In embodiments, the methods are for the treatment of vascular malformations or cancer.

The invention provides a gene detection kit for molecular diagnosis of hemangioma and vascular malformation and application. Specifically, the invention provides a gene combination for determining molecular diagnosis of hemangioma and vascular malformation, and based on NGS panel + RNAseq gene sequencing, the gene combination for molecular diagnosis of hemangioma and vascular malformation provided by the invention can be applied to all molecular diagnosis and liquid biopsy related to hemangioma and vascular malformation. The correlation between mutation sites and abundance and disease phenotypes is disclosed, so that the method has a relatively great clinical popularization and application prospect.

The disclosure relates in part to the discovery that slow-flow vascular malformations (which can be venous and / or lymphatic) can be treated using direct intralesional delivery of an active drug, such as but not limited to a mTOR inhibitor, such as but not limited to temsirolimus, or a salt or solvate thereof.

In one aspect, the present invention features a method of inhibiting proliferation and / or reducing survival of a cell comprising a GNAQ polynucleotide or polypeptide having a R183Q or Q209L mutation, comprising contacting the cell with puromycin or a puromycin analog, thereby inhibiting proliferation and / or reducing survival of the cell. In another aspect, a method of treating a vascular malformation or related condition in a subject, comprising administering to the subject an effective amount of puromycin or a puromycin analog is featured. In another aspect, the present invention features a method of identifying a candidate agent that modulates a GNAQ R183Q or Q209L mutation-associated disease, comprising contacting a cell comprising a GNAQ polynucleotide or polypeptide having a R183Q or Q209L mutation with puromycin and a candidate agent and comparing viability of the contacted cell with a reference level of viability, wherein an alteration in viability indicates that the candidate agent modulates the GNAQ R183Q or Q209L mutation-associated disease.

A non-occlusive blood restricting device is provided for delivery by a microcatheter and for treating a vascular malformation. The blood restricting device includes a wire that include first and second sections. The first section is configured to be coiled into a first coil when deployed within the vascular malformation. The first coil includes a spiral or sequence of loops, the spiral or sequence of loops having a gradually decreasing diameter. The first coil is configured to line a neck, a wall, or the neck and the wall of the vascular malformation so as to at least partially cover an orifice of the vascular malformation. The second section is configured to be deployed within a blood vessel, adjacent the vascular malformation. The second section is configured to form a second coil, circumferentially lining a wall of the blood vessel. Other embodiments are also described.

The invention belongs to the field of biological detection, and discloses a gene detection panel for detecting hemangioma and vascular malformation and application of the gene detection panel. The invention discloses a gene detection panel for hemangioma and vascular malformation. Comprising the gene detection panel and is used for detecting hemangioma and vascular malformation; an application of the gene detection panel in preparation of a hemangioma and vascular malformation diagnostic reagent or diagnostic kit; the gene detection panel is applied to a device for auxiliary diagnosis of etiology of hemangioma and vascular malformation patients; and the device is used for auxiliary diagnosis of pathogenesis of hemangioma and vascular malformation patients. The gene detection panel disclosed by the invention can efficiently and accurately identify gene mutation related to hemangioma and vascular deformity, can cover wide genes related to hereditary and sporadic vascular deformity, and can provide accurate information for diagnosis, treatment and prognosis evaluation of diseases.